spacer
home > epc > Spring 2017
PUBLICATIONS

European Pharmaceutical Contractor

epc
Spring 2017

   
Text
PDF
bullet
Data Management & IT Solutions
Spotlight

Transforming Software


Bracket’s Steve Rawbone and Stephane Deleger highlight the advantages of iterative design and user acceptance testing, detailing how this can reduce the complexity of clinical trials.
 
view
download pdf
bullet
DATA MANAGEMENT
Electronic Data Interchange

Destination: Automation


A hands-off approach to trials, through to the automation of processes such as the managing of inventories, is a new industry goal, but Ian Davison at HMD Clinical suggests that this raises its own questions.
 
view
download pdf
bullet
Supply Chain Management
Supply Management
 
Getting Interactive


Utilisation of intelligent IRT systems is the best way to meet the demands of clinical supply management, argues Stefan Dürr at Cenduit, as this can save time and eliminate unnecessary work.
 
view
download pdf
Local Trial Supply

The Hungarian Way


Many countries in the CEE region are now looking to local companies for several supply activities, so Tibor Kovacs at PharmaRoad expands on the reasons why Hungary is leading this trend.
 
view
download pdf
Managing Risk

Risky Business


Nils Markmann at World Courier explains how manufacturers can prepare for growing challenges in the modern mobile supply chain, protecting both themselves and patients.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement